ECKERT & ZIEGLER BG 
By Seneffe - Belgium, March 29, 2013 - Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) announced today its consolidated results for the year ending December 31, 2012.
A summary report including the milestones of 2012 and a selection of consolidated key figures for the twelve months ending December 31, 2012 can be downloaded at:
http://www.bebig.eu/home/investor-relations/financial-reports/interim-results.html:
http://www.bebig.eu/home/investor-relations/financial-reports/interim-results.html
Sales for 2012 reached 31.8 million EUR, compared to 30.4 million EUR in 2011, showing an increase of 4.5%. The main components were income generated by the sales of permanent brachytherapy I-125 radiotherapeutic implants, as well as income from temporary brachytherapy equipment, i.e., HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders").
Operating results reached 5.3 million EUR for the full year 2012, compared to 5.1 million EUR in 2011, showing an increase of 3.9%. Earnings before interest and taxes (EBIT) reached 5.2 million EUR in 2012, versus 5.0 million EUR in 2011, showing an increase of 4.0%.
Cash amounted to 3.3 million EUR at the end of December 2012, versus 5.1 million EUR in December 2011. The equity-to-asset ratio stood at 70.3% at the end of December 2011.
Shareholders Calendar:
Interim Statement 1Q-2013: Friday, May 3, 2013
Annual General Meeting: Thursday, June 13, 2013 (11:30 a.m.)
Half-Year Results 2013: Thursday, August 15, 2013
Interim Statement 3Q-2013: Friday, November 8, 2013
The results and trading updates will be published before market opens on the respective dates.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and is headquartered in Belgium. It has a production facility in Germany and subsidiaries throughout Europe, as well as in India and in Brazil. Eckert & Ziegler BEBIG has also established a worldwide network of distributors and agents to support its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB).
Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir@bebig.eu:
mailto:ir@bebig.eu
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
